Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Janus kinase (JAK) family comprises four intracellular, non-receptor tyrosine kinases: JAK1, JAK2, JAK3, and TYK2. These enzymes are essential mediators of cytokine signaling and play a central role in the JAK-STAT pathway—a key mechanism for transducing signals from extracellular cytokines to the cell nucleus to regulate gene expression. They regulate immune responses, cell growth, proliferation, differentiation, and apoptosis. Dysregulation is implicated in various cancers and autoimmune diseases, making them important therapeutic targets.
Inhibition of JAK kinase activity, blocking downstream STAT signaling.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Janus Kinase Family Protein Tyrosine Kinases (JAK Family).